OneMedNet Corp

OneMedNet Corporation announced it has regained compliance with The Nasdaq Stock Market's minimum bid price requirement of $1.00. The company received notification from Nasdaq on October 13, 2026, stating that its common stock had a closing bid price of at least $1.00 for 10 consecutive business days from September 29 to October 12, 2026. This compliance resolves the previous notification received on April 14, 2026, and the matter is now closed.

OneMedNet Corporation held its 2026 Annual Meeting of Stockholders where key proposals were approved. These included the election of three Class III directors, the ratification of WithumSmith+Brown, PC as the independent auditor, and the approval of an amendment to the 2022 Equity Incentive Plan to increase the share reserve by 1,000,000 shares. Additionally, stockholders approved an amendment to the company's certificate of incorporation to effect a reverse stock split.

OneMedNet Corporation announced a new agreement to supply its regulatory decision-grade, multi-modal imaging-centric iRWD™ platform data for the development and training of a foundational AI model. The initial contract is valued in excess of $11.5 million, with immediate data delivery. This deal is seen as a significant validation of OneMedNet's capabilities in curating and delivering high-quality, de-identified healthcare data at scale, further expanding its network which now includes over 90 million patient journeys and 270 million clinical studies.

OneMedNet Corp has scheduled its 2026 Annual Meeting of Stockholders for September 18, 2026, with August 11, 2026, as the record date for voting. Due to a change in the meeting date by more than 30 days from the previous year's anniversary, the company has updated the deadlines for shareholder proposals and director nominations. All shareholder proposals and director nominations must be received by August 5, 2026, to be considered for the upcoming meeting.

OneMedNet Corporation filed an Amendment No. 1 to its S-1 registration statement, registering up to 11,680,535 shares of Common Stock for resale by various selling stockholders. This includes 8,500,000 shares potentially issued under a Standby Equity Purchase Agreement with Yorkville, and 3,180,535 shares previously issued to directors Dr. Thomas Kosasa and Dr. Jeffrey Yu through investments and compensation conversions. The company will not receive any proceeds from the sale of these registered shares, which could lead to significant dilution for existing shareholders.

OneMedNet Corp. has registered up to 11,680,535 shares of common stock for resale by selling stockholders. This includes 8,500,000 shares issuable under a new Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $25 million, and shares issued to directors Dr. Thomas Kosasa and Dr. Jeffrey Yu through recent private placements. The company will not receive any proceeds from the resale of these shares, which are being registered to satisfy certain registration rights.

OneMedNet Corporation has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., providing the company with the option to sell up to $25 million of its common stock. The shares would be purchased at 97% of the market price, with the company retaining the right to set a minimum acceptable price. The agreement includes limitations on Yorkville's beneficial ownership and an exchange cap on the total number of shares issued.

OneMedNet Corporation announced that its iRWD Network has surpassed 90 million patient journeys and 270 million studies, with its healthcare partner network now exceeding 2,300 sites. This represents a 12.5% increase in patient journeys since April 2026 and a 30% expansion in provider sites in less than a year. The company highlighted this progress as direct execution against its strategic priorities for long-term value creation, meeting accelerating demand for Real-World Data and AI foundational models across various medical specialties.

OneMedNet Corp reported a net loss of $2.5 million for the first quarter of 2026, an increase from $1.9 million in the prior year, while total revenue decreased to $96,000. The company's cash balance of $233,000 as of March 31, 2026, is deemed inadequate to fund operations for the next twelve months, leading management to raise substantial doubt about its ability to continue as a going concern. OneMedNet plans to secure additional working capital through equity or debt offerings to support its operations.

OneMedNet Corp (ONMD) filed an Amendment No. 1 to its Form 10-K, providing previously omitted information regarding corporate governance, executive compensation, security ownership, and related party transactions. The amendment detailed 2025 compensation for named executive officers, including CEO Aaron Green ($1.11M), CFO Robert Golden ($0.50M), and CMO Dr. Jeffrey Yu ($0.54M). It also disclosed significant beneficial ownership by Dr. Thomas Kosasa (30.4%) and Dr. Jeffrey Yu (15.2%), along with related party investments and conversions of notes. Notably, the filing identified several delinquent Section 16(a) reports for directors and executive officers during 2025.